Role of cell-free plasma DNA as a diagnostic marker for prostate cancer
Role of cell-free plasma DNA as a diagnostic marker for prostate cancer
复制标题
DOI：
10.1196/annals.1318.013
复制
发表时间：
2004-01-01
期刊：
影响因子：
--
通讯作者：
Swaminathan, R
中科院分区：
文献类型：
--
作者：
Allen, D;Butt, A;Swaminathan, R
最近的证据表明癌症患者的血浆游离 DNA 水平升高。本研究的目的是量化和比较前列腺癌、前列腺上皮内瘤变 (PIN) 和良性前列腺肥大 (BPH) 患者的无细胞血浆 DNA 水平，以检查其是否提供有用的诊断测试。血液样本取自 37 名前往诊所进行前列腺活检的患者。在活检前、活检后 1 小时内以及两周后采集样本。使用 QIAamp 血液试剂盒 (Qiagen) 提取 DNA，并使用实时定量 PCR 检测 β-珠蛋白基因，以基因组当量/毫升血浆 (GE/mL) 为单位测量血浆 DNA。活检前，BPH 患者的血浆 DNA 浓度为 936 GE/mL（中位数；范围：633-2074 GE/mL），而癌症和 PIN 患者的 DNA 水平显着较高，分别为 1734 GE/mL（中位数；范围：351-3131 GE/mL；P = 0.01）和 1780 GE/mL（中位数；范围：1514-2732 GE/mL；P = 0.01）。 P = 0.04），分别。活检前后血浆DNA浓度的比较显示，活检后60分钟，BPH（1494 GE/mL；范围：613-2522 GE/mL；P = 0.029）和癌症（2758；范围：1498-5226 GE/mL；P = 0.007）患者的值显着较高。数据的 ROC 分析表明，当以 1000 GE/mL 的 DNA 浓度作为恶性肿瘤或 PIN 的指标时，敏感性为 85%，特异性为 73%。数据表明，无细胞血浆 DNA 的定量可能在区分良性和恶性前列腺疾病方面具有重要的诊断作用。
Recent evidence has shown elevated levels of cell-free plasma DNA in cancer patients. The aim of the present study was to quantify and compare the levels of cell-free plasma DNA in patients with prostate cancer, prostatic intraepithelial neoplasia (PIN), and benign prostatic hypertrophy (BPH) to examine if it offered a useful diagnostic test. Blood samples were obtained from 37 patients attending a clinic for prostate biopsies. Samples were taken prior to biopsy, within 1 hour of the biopsy, and then 2 weeks later. DNA was extracted using a QIAamp blood kit (Qiagen) and plasma DNA measured, in genome equivalents/milliliter plasma (GE/mL), using real-time quantitative PCR for the beta-globin gene. Prior to biopsy, plasma DNA concentration in BPH patients was 936 GE/mL (median; range: 633-2074 GE/mL), while cancer and PIN patients had significantly higher levels of DNA at 1734 GE/mL (median; range: 351-3131 GE/mL; P = 0.01) and 1780 GE/mL (median; range: 1514-2732 GE/mL; P = 0.04), respectively. Comparison of plasma DNA concentration before and after biopsy showed that 60 minutes after biopsy values were significantly higher in both BPH (1494 GE/mL; range: 613-2522 GE/mL; P = 0.029) and cancer (2758; range: 1498-5226 GE/mL; P = 0.007) patients. ROC analysis of the data indicated a sensitivity of 85% and a specificity of 73% when DNA concentration of 1000 GE/mL was taken as an indicator of malignancy or PIN. The data suggest that quantification of cell-free plasma DNA may have an important diagnostic role in distinguishing benign and malignant prostate disease.